VRTX (Vertex Pharmaceut)
All Pro Portfolios with VRTX

People owning VRTX also tend to own:: EXPEIACIMCDXECHGSIIDIXITMN

All Do-It-Yourself Portfolios with VRTX
  • News For Selected Stock
  • Related stories on theStreet.com
  • videos related to etf's
  • No videos found
  •  
  • blogs related to etf's
  • No blogs found
  •  

Why I Love This Stock

By:barrons3

Date:04 29 09

Pete Najarian has spotted some unusual options activity. He speculates that call buying in Vertex Pharma (VRTX) could mean it’s a takeover target -- with JNJ (JNJ) rumored to be sniffing around.

Not yet rated
Rate now:

By:barrons3

Date:01 07 09

Takeover targets are wide ranging and include Biogen [BIIB], Amylin (AMLN), OSI Pharma [OSIP], and Vertex Pharma [VRTX], says Huckman.

Not yet rated
Rate now:

By:Trading Nymph

Date:12 30 08

1:30

Not yet rated
Rate now:

By:barrons3

Date:09 27 08

Pfizer (PFE) and Schering-Plough (SGP) continue to invest in R&D, but have battered shares, so they outrank Wyeth (WYE). Regeneron Pharmaceutical (REGN) rates higher than more richly valued biotechs like Amgen (AMGN) or Vertex Pharmaceuticals (VRTX). The idea here is inspired by the value-investing tradition: Buy a dollar of research for fifty cents.

Not yet rated
Rate now:

By:barrons2

Date:08 16 08

Not all of the focus is on products already in the market, however. Vertex Pharmaceuticals (VRTX), another company that some investors view as an eventual takeover candidate, is developing Telaprevir, a substance that promises to reduce the time needed to treat hepatitis-C, a potentially fatal liver ailment. Telaprevir is currently in stage III testing, the last phase of the clinical- trial process. Vertex has worked with Johnson & Johnson (JNJ) in developing that drug.

Not yet rated
Rate now:

By:barrons2

Date:06 14 08

Market Perform - Price 32.96 on June 10
by Rodman & Renshaw

Telaprevir [looks like] the most promising therapy for hepatitis-C in development....With headline risk in next six to nine months from competitors' [advance], we believe VRTX shares will perform in line with biotech indexes. Reiterate our Market Perform. Market cap: $4.6 billion.

Not yet rated
Rate now:

By:Pro

Date:11 30 -1

Vertex (VRTX) was upgraded to Outperform at Cowen and Company. Recent results with VRTX's protease inhibitor telaprevir is likely to have a role in treatment experienced HCV leading to more potential for upside.

Not yet rated
Rate now:

By:Pro

Date:11 30 -1

Vertex Pharma (VRTX) was upgraded from Underperform to Market Perform, Wachovia said. Major potential threat to telaprevir is now behind the company.

Not yet rated
Rate now:

By:Pro

Date:11 30 -1

Vertex Pharma (VRTX) was downgraded from Buy to Hold, Citigroup said. $25 price target. Company lacks potential catalysts in 2008, and competition is heating up for telaprevir.

Not yet rated
Rate now:

By:Pro

Date:11 30 -1

Biotech Buzz: Fresh News From JP Morgan Confab
Adam Feuerstein delivers the buzz-worthy biotech news from Day One of the confab.

Click here to watch the video.

Not yet rated
Rate now:

Why I Hate This Stock

By:kanderson

Date:04 28 07

spec

Not yet rated
Rate now:
Add Your Comments  
Stock VRTX
Allowed HTML tags: <a><b><i><img>
  Login to post your comments
Four Must-See Charts: Stem Cell ...

By Stockpickr Staff Posted on July 2, 2009 Developments in the stem cell world are starting to get very interesting. On Tuesday, General Electric (GE) signed an exc...

07.02.09 | 15:19 PM
Stockpickr's Picks of the Day: J...

By Rebecca Corvino Posted on July 2, 2009 Every day, Stockpickr members are creating and sharing stock ideas with each other through various platforms. If you're not al...

07.02.09 | 13:43 PM
Cramer's Take on Headline Stocks...

By Rebecca Corvino Posted at 12:30 p.m. EDT on July 2, 2009 Making Thursday's headlines and sending stocks lower were reports that June saw the loss of 467,000 more job...

07.02.09 | 12:31 PM
Dividend Stocks for the Week

By Stockpickr Staff Posted on July 2, 2009 Some investors assume that at this time of year, it's the summer doldrums for the stock market. After all, as the saying goe...

07.02.09 | 11:02 AM
more articles
General market Technical Analysi...
11.14.07 | 22:55 PM From author ZA
The Presidential/Political Thread
01.02.08 | 08:05 AM From author Dave Cox
what happened to DSCO?
07.02.09 | 11:45 AM From author Disco Duck
Nymph's Trading Daily Trading Diary
04.13.09 | 01:10 AM From author Trading Nymph
more forums
Q. Whose stock market knowledge is ...
07.03.09 | 19:42 PM Asked by kjp712

A. Unless you are hooked on Cody due to a
generational bias, keep movin along . .
. unless you are hooked on his sexually
biased co-host . . . you know,
whats-her-name.

today 's lists
Analyst Upgrades

Analyst Upgrades for July 1, 2009. Read more here. more

Rising on Unusual Volume

Here are some stocks that moved up on unusual volume on July 1, 2009. more

Stocks With Unusual Option Activity

Unusually active options can often indicate that a major event in a stock is about to take place, or that unsophisticated investors (using options in lieu of leverage) are ... more